Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Early Post Radiation Neuropathy: Complex Pathogenesis Including Microvasculitis and Tumor Spread
Neuromuscular and Clinical Neurophysiology (EMG)
P14 - Poster Session 14 (11:45 AM-12:45 PM)
10-001
Radiation-induced neuropathy typically occurs up to decades after radiation from neural fibrosis with insidious, painless progressive weakness.  Reports of early radiation-associated neuropathies are lacking.
To describe patients with early radiation-induced peripheral nerve injury and investigate potential pathogenic mechanism(s).
Patient cases labeled as “radiation neuropathy” were electronically retrieved from our electromyography (EMG) and Mayo Data Explorer databases between January 2014 to August 2022.  Inclusion criteria included neural deficits within 6 months of radiation, EMG testing, and available follow-up nerve imaging. 
Twenty-two patients (9 female, mean age 63 years [range 34-84]) were identified with a history of squamous (n=6), prostate (n=5), breast (n=3), rectal (n=2), hematologic (n=2), and other (n=4) cancers.  Average radiation dose was 4491 cGy (range 1000-7208).  Time to symptom onset averaged 1.9 months (range 0-4). Pre-radiation chemotherapy occurred in most (n=16).  All neuropathies occurred in the same radiation territory, but most neuropathies (n=17) occurred distal to the radiation site.  EMG-confirmed neuropathies included radiculopathies (n=10), brachial and lumbosacral plexopathies (n=10), and mononeuropathies (n=2).  EMG myokymia was seen in few (n=6).  Patients reported primarily painful paresthesias (n=18) and weakness (n=18).  Clinical courses were monophasic (n=8), progressive (n=8), static (n=2), and unclear without follow-up (n=4).  Follow-up neural MRI did not suggest infiltrative disease (n=21), but based on tumor location and progressive course, microscopic infiltration was suspected.  Two patients had nerve biopsies showing prominent inflammation around epineural microvessels with vessel wall injury (microvasculitis).  One biopsy revealed neoplastic spread of rectal squamous cell cancer.  Steroid burst therapy was attempted in 6 patients; 5 reported benefits, and 4 had monophasic courses.

Early-onset post radiation neuropathies having pain and monophasic courses are supported by steroid response and biopsy-confirmed microvasculitis to have an inflammatory-immune mechanism.  Exclusion of infiltrative cancer and an idiosyncratic radiation injury with progressive course are important to consider. 

Authors/Disclosures
Michael Paul Skolka, MD (Mayo Clinic)
PRESENTER
Dr. Skolka has nothing to disclose.
Joon H. Uhm, MD, FRCP(C), FAAN (Mayo Clinic) Dr. Uhm has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Zai Lab.
Daniel Ma, MD (Mayo Clinic) Dr. Ma has nothing to disclose.
Ashley Santilli, MD (Mayo Clinic) Dr. Santilli has nothing to disclose.
James Bryan*use387890 Meiling (Texas College of Osteopathic Medicine) Mr. Meiling has nothing to disclose.
Paola Sandroni, MD, PhD, FAAN (Mayo Clinic) Dr. Sandroni has nothing to disclose.
Nathan P. Staff, MD, PhD, FAAN (Mayo Clinic) Dr. Staff has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stem Cell Research & Therapy. Dr. Staff has received research support from National Institutes of Health.
Marcus Vinicius Rocha Pinto, MD (Mayo Clinic) Dr. Pinto has nothing to disclose.
P. James B. Dyck, MD, FAAN (Mayo Clinic) Dr. Dyck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea/Ionis.
Christopher J. Klein, MD, FAAN (Mayo Clinic) Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sangamo Therapeutics . Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Faze Medicine .